Sign in
APUS Stock Price, Chart, Stats & News
Apimeds Pharmaceuticals US, Inc
Save
Apimeds Pharmaceuticals US, Inc (APUS) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
APUS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -55.76% |
ROE | -139.58% |
D/E | 0.06x |
Interest coverage ratio | -49.77x |
APUS valuation
P/E | – |
P/S | – |
P/B | 0.29x |
P/CF | -0.46x |
P/FCF | -0.46x |
P/OCF | -0.46x |
PEG | 0.01x |
EV multiple | -1.76x |
About
Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis.
Similar securities
Based on sector and market capitalization
Report issue